Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Genetic Epilepsy Clear all
Recruiting Phase 2 Interventional

Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study

NCT05104983
View directory record Official record
Conditions
Tuberous Sclerosis Complex, Epilepsy
Interventions
Sirolimus, Placebo
Drug
Lead sponsor
Darcy Krueger
Other
Eligibility
1 Day to 6 Months
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jul 22, 2026, 9:57 AM EDT
Enrolling by invitation No phase listed Observational

SLC13A5 Deficiency Natural History Study - United States Only

NCT06144957
View directory record Official record
Conditions
Citrate Transporter Deficiency, Epilepsy, Rare Diseases, Movement Disorders, Genetic Disorder, SLC13A5 Deficiency, EIEE25, Kohlschutter-Tonz Syndrome (Non-ROGDI), Citrate Transporter Disorder, DEE25
Interventions
Not listed
Lead sponsor
TESS Research Foundation
Other
Eligibility
Not listed
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Palo Alto, California • Providence, Rhode Island • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo

NCT00179517
View directory record Official record
Conditions
Seizure Disorder, Hypogonadism, Erectile Dysfunction
Interventions
Anastrozole 1mg, Placebo Oral Tablet
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Jul 22, 2026, 9:57 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Genetic Disease Gene Identification

NCT00916903
View directory record Official record
Conditions
Congenital Vertical Talus, Familial Encephalopathy With Neuroserpin Inclusion Bodies, Idiopathic Generalised Epilepsy, Familial Dementia, X-linked Mental Retardation
Interventions
Not listed
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
6 Months and older
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2015
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Jul 22, 2026, 9:57 AM EDT
Completed No phase listed Observational

Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC

NCT01767779
View directory record Official record
Conditions
Tuberous Sclerosis Complex
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Day to 6 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
5
States / cities
Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol

NCT03467113
View directory record Official record
Conditions
Dravet Syndrome, Lennox Gastaut Syndrome
Interventions
ZX008 0.2 to 0.8 mg/kg/day, Cannabidiol
Drug
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Atlanta, Georgia • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Jul 22, 2026, 9:57 AM EDT
Recruiting No phase listed Observational

Baker Gordon Syndrome Natural History Study

NCT06399952
View directory record Official record
Conditions
Rare Diseases, Autism or Autistic Traits, Development Delay, SYT-SSX Fusion Protein Expression, Sleep Disorder, Epilepsy, Generalized, Motor Delay
Interventions
Brain Magnetic Resonance Imaging (MRI), Whole Genome Sequencing, Induced Pluripotential Stem Cells
Diagnostic Test · Genetic · Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
0 Years to 99 Years
Enrollment
50 participants
Timeline
2024 – 2027
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jul 22, 2026, 9:57 AM EDT
Terminated Phase 3 Interventional Results available

Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy

NCT05604170
View directory record Official record
Conditions
Tuberous Sclerosis Complex
Interventions
Ganaxolone
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
1 Year to 65 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Jul 22, 2026, 9:57 AM EDT
Recruiting No phase listed Observational

CNKSR2 Natural History Study

NCT06500260
View directory record Official record
Conditions
Developmental Dysphasia, Epileptic Encephalopathy, Childhood-Onset, X-Linked Intellectual Disability
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Years to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2024 · Synced Jul 22, 2026, 9:57 AM EDT
Recruiting No phase listed Observational

ESIS in Pediatric DRE

NCT05469373
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
Sarah Katie Ihnen
Other
Eligibility
1 Year to 30 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jul 22, 2026, 9:57 AM EDT
Completed No phase listed Observational

Genetic Study of Familial Epilepsy

NCT00006059
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older
Enrollment
898 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Phase 1 Interventional

Carisbamate Safety Study in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome

NCT04062981
View directory record Official record
Conditions
Lennox Gastaut Syndrome
Interventions
Carisbamate
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
2 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
Baltimore, Maryland • Lebanon, New Hampshire • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Phase 2 Interventional Results available

Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex

NCT02849457
View directory record Official record
Conditions
Tuberous Sclerosis Complex
Interventions
Early Vigabatrin, Delayed Vigabatrin (Placebo)
Drug
Lead sponsor
Martina Bebin
Other
Eligibility
1 Day to 6 Months
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Jul 22, 2026, 9:57 AM EDT
Recruiting Not applicable Interventional

Molecular Genetic Mechanisms of Infantile Epilepsies and the Impact of Genetic Diagnosis

NCT06701084
View directory record Official record
Conditions
Neonatal Epilepsy, Infantile Epilepsy
Interventions
Genomic Sequencing
Genetic
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jul 22, 2026, 9:57 AM EDT
Recruiting No phase listed Observational

Genetic Markers of Cardiovascular Disease in Epilepsy

NCT02824822
View directory record Official record
Conditions
Epilepsy, Seizures, Syncope, Channelopathy, Cardiomyopathies
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

NCT02224560
View directory record Official record
Conditions
Epilepsy, Lennox Gastaut Syndrome
Interventions
GWP42003-P, Placebo control
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 55 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Jul 22, 2026, 9:57 AM EDT
Completed No phase listed Observational

Ketogenic Diet in Lafora Disease

NCT00007124
View directory record Official record
Conditions
Lafora Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Phase 3 Interventional Results available

Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults

NCT00368251
View directory record Official record
Conditions
Unverricht-Lundborg Disease
Interventions
Placebo, BRV 2.5 mg, BRV 25 mg, BRV 50 mg
Other · Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
4
States / cities
San Francisco, California • Gainesville, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Jul 22, 2026, 9:57 AM EDT
Terminated Phase 2 Interventional Results available

A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease

NCT02473445
View directory record Official record
Conditions
Mitochondrial Diseases
Interventions
Cysteamine Bitartrate
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
5
States / cities
San Diego, California • Stanford, California • Akron, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Jul 22, 2026, 9:57 AM EDT
Completed No phase listed Observational

Phenotype and Etiology of Pallister-Hall Syndrome

NCT00001404
View directory record Official record
Conditions
Malformations, Multiple Abnormalies, Polydactyly
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
1,170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2016
U.S. locations
3
States / cities
Los Angeles, California • Bethesda, Maryland • Greenwood, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies

NCT03650452
View directory record Official record
Conditions
Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome
Interventions
TAK-935, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 17 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Jul 22, 2026, 9:57 AM EDT
Recruiting Phase 3 Interventional

An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

NCT05066217
View directory record Official record
Conditions
Lennox Gastaut Syndrome
Interventions
Clemizole HCl, Placebo
Drug
Lead sponsor
Epygenix
Industry
Eligibility
2 Years to 55 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
24
States / cities
Little Rock, Arkansas • Orange, California • Wilmington, Delaware + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 22, 2026, 9:57 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

MRI in Autosomal Dominant Partial Epilepsy With Auditory Features

NCT00072813
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
21 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2003
U.S. locations
2
States / cities
Bethesda, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 9:57 AM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome

NCT03355209
View directory record Official record
Conditions
Lennox Gastaut Syndrome
Interventions
ZX008 0.2 or 0.8 mg/kg/day, Matching Placebo
Drug
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Eligibility
2 Years to 35 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
30
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Jul 22, 2026, 9:57 AM EDT